What the reform is about
We are setting up a compliance and assurance function to maintain the integrity of the Prescribed List and provide assurance that policy outcomes are being met.
How we will achieve this
Our first step was to develop the Prescribed List Compliance Strategy. The strategy:
- outlines the principles which govern our compliance and enforcement functions and priorities
- describes suspected and actual non-compliance
- sets out the steps we may take if there are concerns about non-compliant activities or behaviours
- will apply to all Prescribed List stakeholders, such as health professionals, private hospitals, private health insurers, clinicians, sponsors and manufacturers
- takes into account suggestions from stakeholders.
Timeline
We undertook consultation on proposed compliance, assurance and information sharing measures. We have released the stakeholder feedback analysis reports:
- Consultation paper 7 - Proposed compliance, assurance and information sharing measure - Stakeholder feedback analysis report
- Consultation paper 8a - Gifts, benefits and discounts reporting requirements – Stakeholder feedback analysis report
- Consultation paper 8b - Alignment of amount charged for supply of a device with corresponding PL benefit – Stakeholder feedback analysis report
Past activities
Date | Activity |
---|---|
23 May to 13 June 2024 | Further consultation on two compliance measures: 2) Alignment of amount charged for supply of a device with corresponding PL benefit |
12 July to 10 August 2023 | Consultation on the proposed measures for compliance assurance and information sharing |
18 May 2023 | Released the Prescribed List Compliance Strategy and stakeholder feedback report |
September to October 2022 | Consultation on the draft Prescribed List Compliance Strategy |
Date last updated: